ABSTRACT
Os maiores avanços no tratamento das arritmias cardíacas, que geraram propostas de mudança e/ou incorporação de novas tecnologias de tratamento medicamentoso ou intervencionista, referem-se à fibrilação atrial, arritmia sustentada mais frequente na prática clínica, razão pela qual demos maior ênfase a essa análise. Os últimos estudos que têm proporcionado revisões, atualizações e perspectivas das principais diretrizes mundiais são os que envolvem as comparações dos esquemas de combinações de anticoagulação e antiagregação plaquetária em pacientes com fibrilação atrial no contexto da doença arterial coronariana com intervenção planejada ou imediata, bem como os que envolvem a estratégia de ablação por cateteres com opção no início do tratamento da fibrilação atrial nos pacientes com insuficiência cardíaca com fração de ejeção reduzida
The greatest advances in the treatment of cardiac arrhythmias, which have led to proposals of change and/or the incorporation of new drug or intervention treatment technologies, relate to atrial fibrillation, the most common sustained arrhythmia in medical practice, which is why we have placed more emphasis on it in this analysis. The latest studies to have revised, updated, and offered new perspectives on the principal global guidelines are those that involve comparisons of regimens that combine anticoagulation and antiaggregation of platelets in patients with atrial fibrillation within the context of coronary artery disease with planned or immediate intervention, as well of those that involve a catheter ablation strategy as an option at the beginning of treatment for atrial fibrillation in patients with heart failure with reduced ejection fraction
Subject(s)
Humans , Male , Female , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/therapy , Atrial Fibrillation , Warfarin/therapeutic use , Coronary Artery Disease , Stents , Aspirin/therapeutic use , Guidelines as Topic/standards , Catheter Ablation/methods , Hemorrhage , AnticoagulantsABSTRACT
The ACUITY and CRUSADE scores are validated models for prediction of major bleeding events in acute coronary syndrome (ACS). However, the comparative performances of these scores are not known. To compare the accuracy of ACUITY and CRUSADE in predicting major bleeding events during ACS. This study included 519 patients consecutively admitted for unstable angina, non-ST-elevation or ST-elevation myocardial infarction. The scores were calculated based on admission data. We considered major bleeding events during hospitalization and not related to cardiac surgery, according to the Bleeding Academic Research Consortium (BARC) criteria (type 3 or 5: hemodynamic instability, need for transfusion, drop in hemoglobin ≥ 3 g, and intracranial, intraocular or fatal bleeding). Major bleeding was observed in 31 patients (23 caused by femoral puncture, 5 digestive, 3 in other sites), an incidence of 6%. While both scores were associated with bleeding, ACUITY demonstrated better C-statistics (0.73, 95% CI = 0.63 - 0.82) as compared with CRUSADE (0.62, 95% CI = 0.53 - 0.71; p = 0.04). The best performance of ACUITY was also reflected by a net reclassification improvement of + 0.19 (p = 0.02) over CRUSADE’s definition of low or high risk. Exploratory analysis suggested that the presence of the variables ‘age’ and ‘type of ACS’ in ACUITY was the main reason for its superiority. The ACUITY Score is a better predictor of major bleeding when compared with the CRUSADE Score in patients hospitalized for ACS.
Os escores ACUITY e CRUSADE são modelos validados para a predição de eventos de sangramento maior na síndrome coronariana aguda (SCA). Os desempenhos comparativos desses escores, entretanto, são desconhecidos. Comparar a acurácia dos escores ACUITY e CRUSADE para a predição de eventos de sangramento maior nas SCA. Este estudo incluiu 519 pacientes admitidos consecutivamente por angina instável e infarto do miocárdio com e sem supradesnivelamento do segmento ST. Os escores foram calculados tendo por base dados da admissão. Definiu-se sangramento maior como sendo o tipo 3 ou tipo 5 do Consórcio de Pesquisa Acadêmica de Sangramento ( Observou-se sangramento maior em 31 pacientes (23 causados por punção femoral, 5 digestivos e 3 em outros locais), sendo a incidência de 6%. Embora os dois escores tenham se associado com sangramento, o ACUITY demonstrou melhor estatística C (0,73, IC 95% = 0,63 – 0,82) do que o CRUSADE (0,62, IC 95% = 0,53 -0,71; p = 0,04). O melhor desempenho do ACUITY foi também evidenciado pela reclassificação líquida de + 0,19 (p = 0,02) em relação à definição de baixo ou alto risco do CRUSADE. A análise exploratória sugeriu que a presença das variáveis ‘idade’ e ‘tipo de SCA’ no ACUITY foi a principal razão para sua superioridade. O escore ACUITY mostrou-se superior ao CRUSADE para a predição de sangramento maior em pacientes hospitalizados por SCA.
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Acute Coronary Syndrome/complications , Hemorrhage/diagnosis , Hemorrhage/etiology , Risk Assessment/methods , Age Factors , Angina, Unstable/complications , Hospitalization , Hemorrhage/classification , Myocardial Infarction/complications , Prognosis , Reference Values , Reproducibility of Results , Sensitivity and Specificity , Sex FactorsABSTRACT
BACKGROUND: The ACUITY and CRUSADE scores are validated models for prediction of major bleeding events in acute coronary syndrome (ACS). However, the comparative performances of these scores are not known. OBJECTIVE: To compare the accuracy of ACUITY and CRUSADE in predicting major bleeding events during ACS. METHODS: This study included 519 patients consecutively admitted for unstable angina, non-ST-elevation or ST-elevation myocardial infarction. The scores were calculated based on admission data. We considered major bleeding events during hospitalization and not related to cardiac surgery, according to the Bleeding Academic Research Consortium (BARC) criteria (type 3 or 5: hemodynamic instability, need for transfusion, drop in hemoglobin ≥ 3 g, and intracranial, intraocular or fatal bleeding). RESULTS: Major bleeding was observed in 31 patients (23 caused by femoral puncture, 5 digestive, 3 in other sites), an incidence of 6%. While both scores were associated with bleeding, ACUITY demonstrated better C-statistics (0.73, 95% CI = 0.63 - 0.82) as compared with CRUSADE (0.62, 95% CI = 0.53 - 0.71; p = 0.04). The best performance of ACUITY was also reflected by a net reclassification improvement of + 0.19 (p = 0.02) over CRUSADE's definition of low or high risk. Exploratory analysis suggested that the presence of the variables 'age' and 'type of ACS' in ACUITY was the main reason for its superiority. CONCLUSION: The ACUITY Score is a better predictor of major bleeding when compared with the CRUSADE Score in patients hospitalized for ACS.
Subject(s)
Acute Coronary Syndrome/complications , Hemorrhage/diagnosis , Hemorrhage/etiology , Risk Assessment/methods , Age Factors , Aged , Aged, 80 and over , Angina, Unstable/complications , Female , Hemorrhage/classification , Hospitalization , Humans , Male , Middle Aged , Myocardial Infarction/complications , Prognosis , Reference Values , Reproducibility of Results , Sensitivity and Specificity , Sex FactorsABSTRACT
Background: The TIMI Score for ST-segment elevation myocardial infarction (STEMI) was created and validated specifically for this clinical scenario, while the GRACE score is generic to any type of acute coronary syndrome. Objective: Between TIMI and GRACE scores, identify the one of better prognostic performance in patients with STEMI. Methods: We included 152 individuals consecutively admitted for STEMI. The TIMI and GRACE scores were tested for their discriminatory ability (C-statistics) and calibration (Hosmer-Lemeshow) in relation to hospital death. Results: The TIMI score showed equal distribution of patients in the ranges of low, intermediate and high risk (39 %, 27 % and 34 %, respectively), as opposed to the GRACE Score that showed predominant distribution at low risk (80 %, 13 % and 7%, respectively). Case-fatality was 11%. The C-statistics of the TIMI score was 0.87 (95%CI = 0.76 to 0.98), similar to GRACE (0.87, 95%CI = 0.75 to 0.99) - p = 0.71. The TIMI score showed satisfactory calibration represented by χ2 = 1.4 (p = 0.92), well above the calibration of the GRACE score, which showed χ2 = 14 (p = 0.08). This calibration is reflected in the expected incidence ranges for low, intermediate and high risk, according to the TIMI score (0 %, 4.9 % and 25 %, respectively), differently to GRACE (2.4%, 25% and 73%), which featured middle range incidence inappropriately. Conclusion: Although the scores show similar discriminatory capacity for hospital death, the TIMI score had better calibration than GRACE. These findings need to be validated populations of different risk profiles. .
Fundamento: O Escore TIMI para infarto com supradesnível do segmento ST (IAMcSST) foi criado e validado especificamente para este cenário clínico, enquanto o Escore GRACE é genérico para qualquer tipo de síndrome coronariana aguda. Objetivo: Identificar qual dos escores, TIMI ou GRACE, apresenta melhor desempenho prognóstico em pacientes com IAMcSST. Métodos: Foram incluídos 152 indivíduos consecutivamente internados por IAMcSST. Os escores TIMI e GRACE foram testados quanto a sua capacidade discriminatória (estatística-C) e calibração (teste Hosmer-Lemeshow), em relação ao desfecho óbito hospitalar. Resultados: O Escore TIMI apresentou distribuição equitativa de pacientes nas faixas de baixo, intermediário e alto risco (39%, 27% e 34%, respectivamente), diferente do Escore GRACE que apresentou distribuição predominante em baixo risco (80%, 13% e 7%, respectivamente). A letalidade da amostra foi de 11%. A estatística-C do Escore TIMI foi de 0,87 (95% IC = 0,76 - 0,98), semelhante ao GRACE (0,87; 95% IC = 0,75-0,99) - p = 0,71. O Escore TIMI apresentou calibração satisfatória, representada por χ2 de 1,4 (p = 0,92), nitidamente superior à calibração do Escore GRACE, que apresentou χ2 de 14 (p = 0,08). Esta calibração se reflete em incidências esperadas para as faixas de baixo, intermediário e alto risco de acordo com o Escore TIMI (0%, 4,9% e 25%, respectivamente), diferente do GRACE (2,4%, 25% e 73%) que caracterizou inadequadamente a faixa intermediária. Conclusão: Os escores TIMI e GRACE apresentam semelhante capacidade discriminatória em relação a óbito hospitalar, porém o Escore TIMI possui calibração superior ao GRACE. Para populações de risco diferente da nossa amostra, esta conclusão ...
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Acute Coronary Syndrome/diagnosis , Myocardial Infarction/diagnosis , Risk Assessment/methods , Acute Coronary Syndrome/mortality , Acute Coronary Syndrome/physiopathology , Hospital Mortality , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Prognosis , Reference Values , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Time FactorsABSTRACT
BACKGROUND: The TIMI Score for ST-segment elevation myocardial infarction (STEMI) was created and validated specifically for this clinical scenario, while the GRACE score is generic to any type of acute coronary syndrome. OBJECTIVE: Between TIMI and GRACE scores, identify the one of better prognostic performance in patients with STEMI. METHODS: We included 152 individuals consecutively admitted for STEMI. The TIMI and GRACE scores were tested for their discriminatory ability (C-statistics) and calibration (Hosmer-Lemeshow) in relation to hospital death. RESULTS: The TIMI score showed equal distribution of patients in the ranges of low, intermediate and high risk (39 %, 27 % and 34 %, respectively), as opposed to the GRACE Score that showed predominant distribution at low risk (80 %, 13 % and 7%, respectively). Case-fatality was 11%. The C-statistics of the TIMI score was 0.87 (95%CI = 0.76 to 0.98), similar to GRACE (0.87, 95%CI = 0.75 to 0.99) - p = 0.71. The TIMI score showed satisfactory calibration represented by χ2 = 1.4 (p = 0.92), well above the calibration of the GRACE score, which showed χ2 = 14 (p = 0.08). This calibration is reflected in the expected incidence ranges for low, intermediate and high risk, according to the TIMI score (0 %, 4.9 % and 25 %, respectively), differently to GRACE (2.4%, 25% and 73%), which featured middle range incidence inappropriately. CONCLUSION: Although the scores show similar discriminatory capacity for hospital death, the TIMI score had better calibration than GRACE. These findings need to be validated populations of different risk profiles.
Subject(s)
Acute Coronary Syndrome/diagnosis , Myocardial Infarction/diagnosis , Risk Assessment/methods , Acute Coronary Syndrome/mortality , Acute Coronary Syndrome/physiopathology , Aged , Female , Hospital Mortality , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Prognosis , Reference Values , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Time FactorsABSTRACT
Fundamento: O valor prognóstico incremental da dosagem plasmática de Proteína C-reativa (PCR) em relação ao Escore GRACE não está estabelecido em pacientes com síndromes coronarianas agudas sem supradesnivelamento do segmento ST (SCA). Objetivo: Testar a hipótese de que a medida de PCR na admissão incrementa o valor prognóstico do escore GRACE em pacientes com SCA. Métodos: Foram estudados 290 indivíduos, internados consecutivamente por SCA, os quais tiveram material plasmático colhido na admissão para dosagem de PCR por método de alta sensibilidade (nefelometria). Desfechos cardiovasculares durante hospitalização foram definidos pela combinação de óbito, infarto não fatal ou angina refratária não fatal. Resultados: A incidência de eventos cardiovasculares durante hospitalização foi 15% (18 óbitos, 11 infartos, 13 anginas), tendo a PCR apresentado estatística-C de 0,60 (95% IC = 0,51 - 0,70; p = 0,034) na predição desses desfechos. Após ajuste para o Escore GRACE, PCR elevada (definida pelo melhor ponto de corte) apresentou tendência a associação com eventos hospitalares (OR = 1,89; 95% IC = 0,92 - 3,88; p = 0,08). No entanto, a adição da variável PCR elevada no modelo GRACE não promoveu incremento significativo na estatística-C, a qual variou de 0,705 para 0,718 (p = 0,46). Da mesma forma, não houve reclassificação de risco significativa com a adição da PCR no modelo preditor (reclassificação líquida = 5,7%; p = 0,15). Conclusão Embora PCR possua associação com desfechos hospitalares, esse marcador inflamatório não incrementa o valor prognóstico do Escore GRACE. .
Background: The incremental prognostic value of plasma levels of C-reactive protein (CRP) in relation to GRACE score has not been established in patients with acute coronary syndrome (ACS) with non-ST segment elevation. Objective: To test the hypothesis that CRP measurements at admission increases the prognostic value of GRACE score in patients with ACS. Methods: A total of 290 subjects, consecutively admitted for ACS, with plasma material obtained upon admission CRP measurement using a high-sensitivity method (nephelometry) were studied. Cardiovascular outcomes during hospitalization were defined by the combination of death, nonfatal myocardial infarction or nonfatal refractory angina. Results: The incidence of cardiovascular events during hospitalization was 15% (18 deaths, 11 myocardial infarctions, 13 angina episodes) with CRP showing C-statistics of 0.60 (95% CI = 0.51-0.70, p = 0.034) in predicting these outcomes. After adjustment for the GRACE score, elevated CRP (defined as the best cutoff point) tended to be associated with hospital events (OR = 1.89, 95% CI = 0.92 to 3.88, p = 0.08). However, the addition of the variable elevated CRP in the GRACE model did not result in significant increase in C-statistics, which ranged from 0.705 to 0.718 (p = 0.46). Similarly, there was no significant reclassification of risk with the addition of CRP in the predictor model (net reclassification = 5.7 %, p = 0.15). Conclusion: Although CRP is associated with hospital outcomes, this inflammatory marker does not increase the prognostic value of the GRACE score. .
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Acute Coronary Syndrome/blood , C-Reactive Protein/analysis , Risk Assessment/methods , Acute Coronary Syndrome/diagnosis , Biomarkers/blood , Hospitalization , Logistic Models , Prognosis , Prospective Studies , Reference Values , Reproducibility of Results , Risk Factors , Sensitivity and SpecificityABSTRACT
BACKGROUND: The incremental prognostic value of plasma levels of C-reactive protein (CRP) in relation to GRACE score has not been established in patients with acute coronary syndrome (ACS) with non-ST segment elevation. OBJECTIVE: To test the hypothesis that CRP measurements at admission increases the prognostic value of GRACE score in patients with ACS. METHODS: A total of 290 subjects, consecutively admitted for ACS, with plasma material obtained upon admission CRP measurement using a high-sensitivity method (nephelometry) were studied. Cardiovascular outcomes during hospitalization were defined by the combination of death, nonfatal myocardial infarction or nonfatal refractory angina. RESULTS: The incidence of cardiovascular events during hospitalization was 15% (18 deaths, 11 myocardial infarctions, 13 angina episodes) with CRP showing C-statistics of 0.60 (95% CI = 0.51-0.70, p = 0.034) in predicting these outcomes. After adjustment for the GRACE score, elevated CRP (defined as the best cutoff point) tended to be associated with hospital events (OR = 1.89, 95% CI = 0.92 to 3.88, p = 0.08). However, the addition of the variable elevated CRP in the GRACE model did not result in significant increase in C-statistics, which ranged from 0.705 to 0.718 (p = 0.46). Similarly, there was no significant reclassification of risk with the addition of CRP in the predictor model (net reclassification = 5.7 %, p = 0.15). CONCLUSION: Although CRP is associated with hospital outcomes, this inflammatory marker does not increase the prognostic value of the GRACE score.
Subject(s)
Acute Coronary Syndrome/blood , C-Reactive Protein/analysis , Risk Assessment/methods , Acute Coronary Syndrome/diagnosis , Aged , Aged, 80 and over , Biomarkers/blood , Female , Hospitalization , Humans , Logistic Models , Male , Middle Aged , Prognosis , Prospective Studies , Reference Values , Reproducibility of Results , Risk Factors , Sensitivity and SpecificityABSTRACT
FUNDAMENTO: Tempo porta-balão adequado (< 120 minutos) é a condição necessária para que a eficácia da angioplastia primária no infarto se traduza em efetividade. OBJETIVO: Descrever a efetividade de um protocolo de qualidade assistencial para redução do tempo porta-balão. MÉTODOS: Entre maio de 2010 e agosto de 2012, foram analisados todos os indivíduos que realizaram angioplastia primária em nosso hospital. O momento porta foi registrado eletronicamente, pela retirada de senha para atendimento na emergência, o que antecede o preenchimento da ficha e a triagem. O momento balão foi definido como o início da abertura da artéria (passagem do primeiro dispositivo). Os primeiros 5 meses de monitoramento corresponderam ao período pré-implementação do protocolo. O protocolo se constituiu de definição do fluxo de ações, desde a chegada do paciente ao hospital, a sensibilização da equipe quanto à priorização do tempo e a apresentação periódica de parecer dos resultados e de possíveis inadequações. RESULTADOS: Foram avaliados 50 indivíduos, divididos em cinco grupos de 10 pacientes sequenciais (um grupo pré e quatro grupos pós-protocolo). O tempo porta-balão referente aos 10 casos registrados antes da implementação do protocolo foi de 200 ± 77 minutos. Após a implementação do protocolo, houve progressiva melhora do tempo porta-balão, para 142 ± 78 minutos nos 10 primeiros pacientes, seguida de 150±50 minutos, 131±37 minutos e, finalmente, 116 ± 29 minutos no três grupos sequenciais de 10 pacientes, respectivamente. Regressão linear entre pacientes sequenciais e tempo porta-balão (r = - 0,41) evidenciou coeficiente de regressão de - 1,74 minutos. CONCLUSÃO: A implementação do protocolo se mostrou efetiva na redução do tempo porta-balão.
BACKGROUND: An adequate door-to-balloon time (<120 minutes) is the necessary condition for the efficacy of primary angioplasty in infarction to translate into effectiveness. OBJECTIVE: To describe the effectiveness of a quality of care protocol in reducing the door-to-balloon time. METHODS: Between May 2010 and August 2012, all individuals undergoing primary angioplasty in our hospital were analyzed. The door time was electronically recorded at the moment the patient took a number to be evaluated in the emergency room, which occurred prior to filling the check-in forms and to the triage. The balloon time was defined as the beginning of artery opening (introduction of the first device). The first 5 months of monitoring corresponded to the period of pre-implementation of the protocol. The protocol comprised the definition of a flowchart of actions from patient arrival at the hospital, the team's awareness raising in relation to the prioritization of time, and provision of a periodic feedback on the results and possible inadequacies. RESULTS: A total of 50 individuals were assessed. They were divided into five groups of 10 sequential patients (one group pre- and four groups post-protocol). The door-to-balloon time regarding the 10 cases recorded before protocol implementation was 200 ± 77 minutes. After protocol implementation, there was a progressive reduction of the door-to-balloon time to 142±78 minutes in the first 10 patients, then to 150±50 minutes, 131±37 minutes and, finally, 116±29 minutes in the three sequential groups of 10 patients, respectively. Linear regression between sequential patients and the door-to-balloon time (r = - 0.41) showed a regression coefficient of - 1.74 minutes. CONCLUSION: The protocol implementation proved effective in the reduction of the door-to-balloon time.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Angioplasty, Balloon, Coronary/methods , Clinical Protocols/standards , Myocardial Infarction/therapy , Time-to-Treatment , Age Factors , Feasibility Studies , Quality of Health Care , Reference Values , Reproducibility of Results , Sex Factors , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: An adequate door-to-balloon time (<120 minutes) is the necessary condition for the efficacy of primary angioplasty in infarction to translate into effectiveness. OBJECTIVE: To describe the effectiveness of a quality of care protocol in reducing the door-to-balloon time. METHODS: Between May 2010 and August 2012, all individuals undergoing primary angioplasty in our hospital were analyzed. The door time was electronically recorded at the moment the patient took a number to be evaluated in the emergency room, which occurred prior to filling the check-in forms and to the triage. The balloon time was defined as the beginning of artery opening (introduction of the first device). The first 5 months of monitoring corresponded to the period of pre-implementation of the protocol. The protocol comprised the definition of a flowchart of actions from patient arrival at the hospital, the team's awareness raising in relation to the prioritization of time, and provision of a periodic feedback on the results and possible inadequacies. RESULTS: A total of 50 individuals were assessed. They were divided into five groups of 10 sequential patients (one group pre- and four groups post-protocol). The door-to-balloon time regarding the 10 cases recorded before protocol implementation was 200 ± 77 minutes. After protocol implementation, there was a progressive reduction of the door-to-balloon time to 142±78 minutes in the first 10 patients, then to 150±50 minutes, 131±37 minutes and, finally, 116±29 minutes in the three sequential groups of 10 patients, respectively. Linear regression between sequential patients and the door-to-balloon time (r = - 0.41) showed a regression coefficient of - 1.74 minutes. CONCLUSION: The protocol implementation proved effective in the reduction of the door-to-balloon time.
Subject(s)
Angioplasty, Balloon, Coronary/methods , Clinical Protocols/standards , Myocardial Infarction/therapy , Time-to-Treatment , Age Factors , Aged , Feasibility Studies , Female , Humans , Male , Middle Aged , Quality of Health Care , Reference Values , Reproducibility of Results , Sex Factors , Time Factors , Treatment OutcomeSubject(s)
Hepatectomy/methods , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Adult , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Treatment OutcomeABSTRACT
Vitamin D deficiency is associated with risk for a first cardiovascular event in the general population, possibly because of inflammation, insulin resistance, and neurohumoral activation. However, its relation with outcomes in acute coronary syndromes has not been reported. To test the hypothesis that severe deficiency of vitamin D is independently associated with cardiovascular mortality during ACS, 206 patients admitted for unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation acute myocardial infarction had 25-hydroxyvitamin D serum levels measured at admission. Severe vitamin D deficiency was defined a priori as a value ≤10 ng/ml. The average concentration of vitamin D was 20 ± 8.2 ng/ml, and 10% of patients were severely deficient (95% confidence interval 6.6% to 15%). Cardiovascular mortality during hospitalization took place in 14 patients, an incidence of 6.8%. Patients with severe vitamin D deficiency had in-hospital cardiovascular mortality of 24%, significantly higher than the 4.9% observed in the remaining patients (relative risk 4.3, 95% confidence interval 1.8 to 10, p = 0.001). After adjustment for Global Registry of Acute Coronary Events (GRACE) score, Gensini angiographic score, and potential confounding variables, severe deficiency of vitamin D remained an independent predictor of in-hospital cardiovascular mortality (odds ratio 14, 95% confidence interval 1.2 to 158, p = 0.03). In conclusion, severe vitamin D deficiency is independently associated with in-hospital cardiovascular mortality in patients with acute coronary syndromes.
